3-氨基甲基-联苯-4-胺 | 828928-23-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基甲基-联苯-4-胺
• 英文名称: 3'-Aminomethyl-biphenyl-4-ylamine
• 英文别名: 4-[3-(aminomethyl)phenyl]aniline
• CAS: 828928-23-0
• 化学式: C₁₃H₁₄N₂
• mdl: MFCD05980590
• 分子量: 198.26
• InChiKey: YEZJBYWVQRNGAU-UHFFFAOYSA-N

物化性质

• 沸点：
  367.1±22.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1<br/>[FR] AMIDES HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DE LA TRPA1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010141805A1

  公开（公告）日：2010-12-09

  Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

  描述了某些杂环酰胺化合物。这些化合物可用于制备药物组合物，以及用于治疗由TRPA1活性介导的疾病状态、紊乱和条件，如疼痛、关节炎、瘙痒、咳嗽、哮喘或炎症性肠病的方法。
• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。
• PROCESS FOR PRODUCING BIARYL COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1914221A1

  公开（公告）日：2008-04-23

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种生产双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱存在下，使芳香族有机化合物与至少一种选自由芳香族有机硼化合物和硼氧化合物组成的组中的化合物反应。
• Adenine derivatives as protein kinase inhibitors
  申请人：B.C.I. PHARMA

  公开号：US11236093B2

  公开（公告）日：2022-02-01

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3′, R4, R4′, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及根据通式(Ⅰ)[化合物(C)，以下同]的适于用作激酶抑制剂的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体，式(Ⅰ)其中A、R1、R2、R3、R3′、R4、R4′、X、Y、Z、T如权利要求书中所定义。本发明进一步涉及一种抑制蛋白激酶活性的体外方法，该方法包括使蛋白激酶与式(I)化合物或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体接触。本发明进一步涉及式（I）化合物本身及其作为药物的用途，以及用于治疗由蛋白激酶介导的选自癌症、炎症性疾病、心血管疾病、病毒引起的疾病、循环系统疾病、纤维增生性疾病和痛觉过敏性疾病的方法。
• ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：B.C.I. PHARMA

  公开号：US20190127379A1

  公开（公告）日：2019-05-02

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R 1 , R 2 , R 3 , R 3′ , R 4 , R 4′ , X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.